Novo Nordisk’s Concizumab Could Be First In New Class For Hemophilia

TFPI Inhibitors Have 20 Years Of Bad History

 
• By Alaric DeArment
Novo Nordisk presented data from its Phase III explorer7 trial of concizumab • Source: Shutterstock

More from Clinical Trials

More from R&D